Pancreatic adenosquamous carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma that arises from the pancreas showing both ductal and squamous differentiation. The squamous component should represent at least 30% of the malignant cellular infiltrate. The prognosis is usually worse than that of ductal adenocarcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pancreatic adenosquamous carcinoma
- Therapeutic area
- Oncology
- pancreatic adenosquamous carcinoma
- adenosquamous carcinoma of pancreas
- adenosquamous carcinoma of the pancreas
- adenosquamous pancreas carcinoma
- pancreas adenosquamous carcinoma
- pancreatic adenoacanthoma
- pancreatic adenosquamous cancer
- pancreatic mixed squamous and adenocarcinoma
- pancreatic mucoepidermoid carcinoma
- PAASC
- Severity
- Severe
- Endocrinology
- Gastroenterology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0005614
- Parent condition
- MONDO:0006074
Related records
Broader conditions (25)
- Adenosquamous carcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine system disorder
- Epithelial neoplasm
- Exocrine pancreatic carcinoma
- Human disease
- Malignant exocrine pancreas neoplasm
- Malignant pancreatic neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Pancreas disorder
Trials (11)
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
- Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
- Switch Maintenance in Pancreatic
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
- Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
- The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Drugs in development (3)
- Minnelide Phase 2
- Pemigatinib Phase 2
- Retifanlimab Phase 2